Articles By Estel Grace Masangkay

71. BI And Lilly To Resubmit Empagliflozin NDA To FDA 6/18/2014

    Boehringer Ingelheim and Eli Lilly & Co. announced that the companies are resubmitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin as treatment for adults with type 2 diabetes.

72. Convergence Posts Positive Phase 2 Results For Orphan Drug In TGN 6/18/2014
    Convergence Pharmaceuticals Holdings reported positive data from the Phase II clinical trial of its orphan drug CNV1014802 in patients with trigeminal neuralgia (TGN), a very severe form of facial pain.
73. Pfizer And Cellectis Sign Into Cancer Immunotherapy Collaboration 6/18/2014
    Pfizer and Cellectis, a biopharmaceutical firm focused on oncology, announced that the companies have signed into a global strategic collaboration to develop Cellectis’ CAR-T immunotherapies aimed at cancer targets.
74. Novartis Files BLA to FDA For Men B Vaccine Bexsero 6/17/2014
    Novartis announced that it has filed a Biologic License Application (BLA) for Bexsero (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to the US Food and Drug Administration (FDA) for marketing approval.
75. Novartis Facility Licensed By FDA For Cell-Culture Flu Vaccines 6/16/2014
    Novartis announced that the U.S. Food and Drug Administration (FDA) has granted license to its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccine.
76. Novo Nordisk Posts Positive Phase 3 Data For Diabetes Drug Victoza 6/16/2014
    Novo Nordisk reported that data from a Phase III study showed that investigational once-daily Victoza (liraglutide [rDNA origin] injection) achieved greater glycemic control compared to placebo, with no aggravation of renal function in adults with type 2 diabetes and moderate renal impairment.
77. Lilly Combo Tablet For Diabetes Reduced Blood Glucose 6/16/2014
    Eli Lilly & Co. and partner Boehringer Ingelheim announced that the investigational combination tablet of empagliflozin and linagliptin was able to reduce blood glucose levels in adults with type 2 diabetes (T2D) in two Phase II trials.
78. Cellectis and CELLforCURE Sign Into Manufacturing Agreement 6/13/2014
    Cellectis and French biopharmaceutical firm LFB Group subsidiary CELLforCURE announced that the companies have signed into an agreement to manufacture clinical batches of Cellectis’ allogenic CART Cells.
79. X-Chem And Pfizer Sign Multi-Target Collaboration Agreement 6/13/2014
    Private biotech X-Chem announced that it has signed into a multi-collaboration target with Pfizer for the development of several treatments for orphan and inflammatory diseases.
80. Takeda Launches Ulcer FDC Tablets In Japan 6/13/2014

    Takeda Pharmaceutical announced the launch of Takelda combination tablets, a fixed-dose combination (FDC) of low-dose aspirin and Takepron (lansoprazole) for peptic ulcers in Japan.